{"id":29932,"date":"2010-10-31T08:19:41","date_gmt":"2010-10-31T08:19:41","guid":{"rendered":"http:\/\/euvolution.com\/futurist-transhuman-news-blog\/access-pharmaceuticals-signs-agreement-with-leading-biopharmaceutical-company-to-develop-coboral-formulation-of-widely-marketed-injectable\/"},"modified":"2010-10-31T08:19:41","modified_gmt":"2010-10-31T08:19:41","slug":"access-pharmaceuticals-signs-agreement-with-leading-biopharmaceutical-company-to-develop-coboral-formulation-of-widely-marketed-injectable","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanotechnology\/access-pharmaceuticals-signs-agreement-with-leading-biopharmaceutical-company-to-develop-coboral-formulation-of-widely-marketed-injectable.php","title":{"rendered":"Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral Formulation of Widely-Marketed Injectable"},"content":{"rendered":"<p>Access Pharmaceuticals, Inc., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral Drug Delivery Technology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Access Pharmaceuticals, Inc., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanotechnology\/access-pharmaceuticals-signs-agreement-with-leading-biopharmaceutical-company-to-develop-coboral-formulation-of-widely-marketed-injectable.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-29932","post","type-post","status-publish","format-standard","hentry","category-nanotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/29932"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=29932"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/29932\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=29932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=29932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=29932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}